A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The…
Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered…
Patients with a condition called monoclonal gammopathy of undetermined significance, characterized by the presence of the abnormal monoclonal or M protein, have a small but…
The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot…
Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the…
The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect…
The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the…
The California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to Poseida Therapeutics to support the clinical development of their P-BCMA-101…
The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by National Health Service (NHS) in Scotland, has amended its initial decision…
Myeloma UK has launched a new clinical trial to identify the best treatment options for myeloma patients classified as high-risk. The study is the…